Novel quercetin glycosides as potent anti-mrsa and anti-vre agents

Recent Patents on Anti-Infective Drug Discovery

Volumn 8, Issue 3, 2013, Pages 198-205

  Hossion, Abugafar M L ^a   Sasaki, Kenji ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Antibacterial; Cell penetration; Multidrug resistant; Quercetin; Quercetin o glycosides; Vancomycin

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMPICILLIN; AMSACRINE; CAMPTOTHECIN; CEPHALOSPORIN; CHLORAMPHENICOL; COUMARIN; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE IV; EPIPODOPHYLLOTOXIN; ERYTHROMYCIN; FLAVANOL DERIVATIVE; FLAVANONE DERIVATIVE; ISOQUERCITRIN; MERBARONE; METICILLIN; MYRICETIN; NOVOBIOCIN; PENICILLIN DERIVATIVE; QUERCETIN DERIVATIVE; QUERCETIN DIACYLGALACTOSIDE; QUERCETIN DIACYLGLYCOSIDE; QUERCETIN MONOACYLGALACTOSIDE; QUINOLONE; RUTOSIDE; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOSIDE; QUERCETIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; DNA REPLICATION; DNA SUPERCOILING; ENTEROCOCCAL INFECTION; ENZYME ACTIVITY; ENZYME INHIBITION; ESCHERICHIA COLI; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PATENT; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; GLYCOSIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PATENTS AS TOPIC; QUERCETIN; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84901752083     PISSN: 1574891X     EISSN: 22124071     Source Type: Journal    
DOI: 10.2174/1574891X08666131210124649     Document Type: Article

References (68)

1. Boehm M, Nabel EG. Angiotensin-converting enzyme 2 - a new cardiac regulator. N Engl J Med 2002; 347: 1795-7.
2. D Miller, V Urdaneta, A Weltman. Center for Disease Control and Prevention, Public Health Dispatch: Vancomycin-resistant Staphylococcus aureus-Pennsylvania. MMWR 2002; 51(40): 902.
3. Levy SB, Marshall B. Nat Med 2004; 10: S122.
4. Barrett JF. Exp Opin Ther Targets 2005; 9: 253.
5. Bryskier A. Exp Rev Anti- Infect Ther 2005; 3: 505.
6. Loffler CA, MacDougall C. Exp Rev Anti-Infect Ther 2007; 5: 961.
7. Mitchell MO. Anti-Infect Agents Med Chem 2007; 6: 243.
8. Arias CA, Murray BEN. Eng J Med 2009; 360: 439.
9. Philip, Y.M., Clement, I.O, Mary, T.C. Antibacterial combination therapy for the treatment of Gram-positive bacterial infection. WO2009081117 (2009).
10. Philip, Y.M., Mary, T.C., Clement, I.O., Anne, C.J. Treatment of multi-drug resistant bacterial infections. WO201000144626 (2010).
11. Philip, Y.M., Mary, T.C., Clement, I.O., Ann, C.J. Antibacterial combination therapy. WO2009013480 (2009).
12. Robinson, R.L., Greenwood, I.N. Vancomycin-HCL solutions and the lyophilization thereof. US4885275 (1989).
13. Kahne, D., Walker, S. Vancomycin analog. US6699836 (2002).
14. Speer BS, Shoemaker NB, Salyers AA. Clin Microb Rev 1992; 5: 387.
15. Elsner H-A, Krüger W, Laufs R, Mack D. Eur J Clin Microbial & Infect Dis 1997; 16: 620.
16. Hachem RY, Hicks K, Huen A, Raad I. Myelosupperssion and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitora in bone marrow transplant recipients. Clin Infect Dis 2003; 37: e8.
17. Baysallar M, Kilic A, Aydogan H, Cilli F, Doganci L. Int J Antimicrob Agents 2004; 23: 510.
18. Navon-Venezia S, Leavitt A, Carmeli YJ. Antimicrob Chemother 2007; 60: 449.
19. Hidron AI, Schuetz AN, Nolte FS, Gould CV, Osborn MK. J Antimicrob Chemother 2008; 61: 1394.
20. Conrath, G., Vacus, J., Barker, N.P. Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof. US6187746 (2001).
21. Rao, D.M., Reddy, P.K. Crystalline form of linezolid. US7718799 (2010).
22. Livermore DM. The need for new antibiotics. Clin Microbial Infect 2004; 10 (Suppl, 4): 1-9.
23. Jacobs MR. Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children. Pediatr Infect Dis J 2003; 22: S109.
24. Barrett CT, Barrett JF. Antibacterials: Are the new entries enough to deal with the emerging resistance problems?. Curr Opin Biotech 2003; 14: 621.
25. Häbich D, von Nussbaum F. Platensimycin, a new antibiotic and "superbug challenger" from nature. Chem Med Chem 2006; 1: 951.
26. Thomson CJ, Power E, Ruebsamen-Waigmann H, Labischinski H. Antibacterial research and development in the 21st century-an industry perspective of the challenges. Curr Opin Microbiol 2004; 7: 445.
27. Maxwell A. DNA gyrase as a drug target. Trends Microbiol 1997; 5: 102.
28. Maxwell A, Lawson DM. The ATP binding site of type II topoisomerases as a target for antibacterial drugs. Curr Top Med Chem 2003; 3: 283.
29. Drlica K, Zhao X. DNA gyrase, topisomerase IV and the 4- quinolones. Microbiol Mol Biol Rev 1997; 61: 377.
30. Heisig P. Inhibitors of bacterial topoisomerases: Mechanisms of action and resistance and clinical aspects. Plant Med 2001; 67: 3.
31. Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, Famechon A, Blanche F. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones. Mol Microbiol 1994; 13: 641.
32. Kato J-I, Nishimura Y, Imamura R, Niki H, Hiraga, S, Suzuki H. New topoisomerases essential for chromosome segregation in E. coli. Cell 1990; 63: 393.
33. Deibler RW, Rahmati S, Zechiedrich EL. Topoisomerase IV, alone, unknots DNA in E coli. Genes Dev 2001; 15: 748.
34. Zechiedrich EL, Khodrusky AB, Bachellier S, Schneider R, Chen D, Lilley DMJ, Cozzarelli NR. Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli. J Biol Chem 2000; 275: 8103.
35. Chen AY, Liu LF. DNA Topoisomerases: Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994; 34: 191.
36. Bellon S, Parsons JD, Wei Y, Haykawa K, Swenson LL, Charifson PS, Lippke JA, Aldape R, Gross CH. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): A single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob Agents Chemother 2004; 48: 1856.
37. Gross CH, Parsons JD, Grossman TH, Charifson PS, Bellon S, Jernee J, Dwyer M, Chambers SP, Markland W, Botfield M, Raybuck SA. Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance. Antimicrob Agents Chemother 2003; 47: 1037.
38. Muñoz R, Bustamante M, de la Campa AG. Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in nivobiocin resistance. J Bacteriol 1995; 177: 4166.
39. Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM, Jones RN, Ambrose PG. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob Agents Chemother 2005; 49: 1775.
40. Jones RN. Should novobiocin be clinically re-evaluated?. Diagn Microbiol Infect Dis 1989; 12: 363.
41. Bloor SJ. An antibacterial kaemferol-diacyl-rhamnoside from Pentachondra pumila. Phytochemistry 1995; 38: 1033.
42. Otsuka N, Liu M-H, Shiota S, Ogawa W, Kuroda T, Hatano T, Tsuchiya T. Anti-methicillin resistant Staphylococcus aureus (MRSA) compounds isolated from Laurus nobilis. Biol Phar Bull 2008; 31: 1794.
43. Liu M-H, Otsuka N, Noyori K, Shiota S, Ogawa W, Kuroda T, Hatano T, Tsuchiya T. Synergistic effect of kaemferol glycosides purified from Laurus nobilis and fluoroquinolones on methicillin- resistant Staphylococcus aureus. Biol Pharm Bull 2009; 32: 489.
44. Kaldas MI, Walle K, van der Woude H, McMillan JM, Walle T. Covalent binding to the flavonoid quercetin to human serum albumin. J Agric Food Chem 2005; 53: 4194.
45. Castillo-Muñoz N, Gómez-Alonso S, García-Romero E, Gómez MV, Velders AH, Hermosín-Gutiérrez I. Flavonol 3-O-glycosides series of Vitis vinifera CV. Petit Verdot red wine grapes. J Agric Food Chem 2009; 57: 209.
46. Peláez LM, Gelber SE, Fox NS, Chasen ST. Inappropriate use of vancomycin for preventing perinatal group B streptococcal (GBS) disease in laboring patients. J Perinat Med 2009; 37: 487.
47. Khodursky AB, Zechiedrich EL, Cozzarelli NR. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci 1995; 92: 11801.
48. Peng H, Marians KJ. Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. J Biol Chem 1993; 268: 24481.
49. Takei M, Fukuda H, Kishii R, Hosaka M. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 2001; 45: 3544
50. Chen AY, Liu LF. Topoisomerases: Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994; 34: 191.
51. Lewis RJ, Singh OM, Smith CV, Skarzynski T, Maxwell A, Wonacott AJ, Wigley DB. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. EMBO J 1996; 15: 1412
52. Roca J, Ishida R, Berger JM, Andoh T, Wang, JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994; 91: 1781.
53. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updates 1999; 2: 38.
54. Hooper DC. From fluoroquinolones to 2-pyridones. N Engl J Med 1991; 324: 384.
55. Kampranis SC, Maxwell A. Conformational changes in DNA gyrase revealed by limited proteolysis. J Biol Chem 1998; 273: 22606.
56. Marians KJ, Hiasa H. Mechanism of quinolone action; A druginduced perturbation of the DNA precedes strand cleavage by topoisomerase IV. J Biol Chem 1997; 272: 9401.
57. Lines, T.C. Method for stabilizing quercetin. US20090088580 (2009).
58. Burger, A.R., Granger, S.P., Scott, I.R. Skin care compositions containing narinGenin and/or quercetin and a retinoid. US5665367 (1997).
59. Yoneyama, M., Iritani, S., Miyake, T. alph-Glycosyl quercetin and it preparation and uses. US5565435 (1996).
60. Tanaka, T., Okemoto, H., Kuwahara, N. Quercetin containing coloring. US5445842 (1995)
61. Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrobial Agents 2005; 26: 343.
62. Razavi SM, Zahri S, Zarrini G, Nazemiyeh H, Mohammadi S. Biological activity of quercetin-3-O-glucoside, a known plant flavonoid. Russ J Bioorganic Chem 2009; 35: 376.
63. Akroum S, Bendjeddon D, Satta D, Lalaoui K. Antibacterial activity and acute toxicity of flavonoids extracted from Mentha longifolia. American-Eurasian J Sci Res 2009; 4: 93.
64. Morand C, Manach C, Crespy V, Remesy C. Quercetin 3-O-betaglucoside is better absorved than other quercetin forms and is not present in rat plasma. Free Radical Res 2000; 33: 667.
65. Sasaki, K., Tsuchiya, T., Hossion, A.M.L. Novel flavanone derivative. US20120202980 (2012).
66. Hossion AML, Otsuka N, Kandahary RK, Tsuchiya T, Ogawa W, Iwado A, Zamami Y, Sasaki K. Design, synthesis and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents. Bioorg Med Chem Lett 2010; 20: 5349.
67. Hossion AML, Zamami Y, Kandahary RK, Tsuchiya T, Ogawa W, Iwado A, Sasaki K. Quercetin diacylglycoside analogues showing dual inhibiton of DNA gyrase and topoisomerase IV as novel antibacterial agents. J Med Chem 2011; 54: 3686.
68. Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999; 43: 459.